Aion Therapeutics Inc.
CSE: AION
Company Overview
Aion Therapeutics Inc. specializes in the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceutical compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations and other medicinal plants through its wholly owned subsidiary, AI Pharmaceuticals Jamaica Limited.
In addition, the company has a joint venture agreement with a private, vertically integrated licensed producer under the Cannabis Act to offer contract tolling extraction services to third-party businesses.
Financial Highlights
$0
Revenue (ttm)
$0
Gross Profit (ttm)
-$0.02
Diluted EPS (ttm)
Management Team
Mr. Graham Simmonds
CEO, COO & Exec. Vice Chair of Board
Mr. Rakesh Malhotra B.Com., C.A., CPA, F.C.A.
Chief Financial Officer
Dr. Stephen D. Barnhill
Exec. Chair of the Board
Dr. Herbert A. Fritsche Jr.
Chief Science Officer
Ms. Patricia Purdy
Corp. Sec.
Key Highlights
Market Capitalization
$1,862,048
Shares Outstanding
30,705,183
Shares Short (% of Float)
15,361 (0%)
Insider Ownership
0%